{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T20:48:15Z","timestamp":1792874895181,"version":"4.5.0"},"reference-count":38,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,5]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>\n                      Dexmedetomidine is a highly selective \u03b1\n                      <jats:sub>2<\/jats:sub>\n                      -agonist with hypnotic, analgesic, and anxiolytic properties. Despite off-label administration, dexmedetomidine has found a niche in critically ill neonates and infants with congenital heart disease because of its minimal effects on respiratory function at sedative doses, facilitating early extubation and fast-track postoperative care. There are little pharmacokinetic data regarding newborns who have immature drug metabolizing capacity and who are at risk for reduced dexmedetomidine clearance and drug toxicity. The aim of this study was to determine the pharmacokinetics of dexmedetomidine in neonates and infants after open heart surgery. This study included 23 evaluable neonates (age, 1 day\u20131 month) and 36 evaluable infants (age, 1 month\u201324 months) after open heart surgery.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>Full-term neonates and infants requiring mechanical ventilation after open heart surgery received dexmedetomidine in a dose-escalation study. Dexmedetomidine was administered as a loading dose over 10 minutes followed by a continuous IV infusion up to 24 hours. Cohorts of 12 infants were enrolled sequentially to receive 0.35, 0.7, or 1 \u03bcg\/kg dexmedetomidine followed by 0.25, 0.5, or 0.75 \u03bcg\/kg\/h dexmedetomidine, respectively. Cohorts of 9 neonates received 0.25, 0.35, or 0.5 \u03bcg\/kg dexmedetomidine followed by 0.2, 0.3, or 0.4 \u03bcg\/kg\/h dexmedetomidine, respectively. Plasma dexmedetomidine concentrations were determined using a validated high-performance liquid chromatography-tandem mass spectrometry assay. A population nonlinear mixed effects modeling approach was used to characterize dexmedetomidine pharmacokinetics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>\n                      Pharmacokinetic parameters of dexmedetomidine were estimated using a 2-compartment disposition model with weight allometrically scaled as a covariate on drug clearance, intercompartmental clearance, central and peripheral volume of distributions and age, total bypass time, and intracardiac shunting on clearance. Dexmedetomidine demonstrated a plasma drug clearance of 657 \u00d7 (weight\/70)\n                      <jats:sup>0.75<\/jats:sup>\n                      mL\/min, intercompartmental clearance of 6780 \u00d7 (weight\/70)\n                      <jats:sup>0.75<\/jats:sup>\n                      mL\/min, central volume of distribution of 88 \u00d7 (weight\/70) L and peripheral volume of distribution of 112 \u00d7 (weight\/70) L for a typical subject with age &gt;1 month with a cardiopulmonary bypass time of 60 minutes and without right-to-left intracardiac shunt. Dexmedetomidine pharmacokinetics may be influenced by age during the neonatal period, weight, total bypass time, and presence of intracardiac shunt.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>Dexmedetomidine clearance is significantly diminished in full-term newborns and increases rapidly in the first few weeks of life. The dependence of clearance on age during the first few weeks of life reflects the relative immaturity of metabolic processes during the newborn period. Continuous infusions of up to 0.3 \u03bcg\/kg\/h in neonates and 0.75 \u03bcg\/kg\/h in infants were well tolerated after open heart surgery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1213\/ane.0000000000000869","type":"journal-article","created":{"date-parts":[[2015,7,28]],"date-time":"2015-07-28T06:41:03Z","timestamp":1438065663000},"page":"1556-1566","source":"Crossref","is-referenced-by-count":69,"title":["Dexmedetomidine Pharmacology in Neonates and Infants After Open Heart Surgery"],"prefix":"10.1213","volume":"122","author":[{"given":"Felice","family":"Su","sequence":"first","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc R.","family":"Gastonguay","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan C.","family":"Nicolson","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MaryAnn","family":"DiLiberto","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alanna","family":"Ocampo-Pelland","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athena F.","family":"Zuppa","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, University of Connecticut, Storrs, Connecticut."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230816","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0022-5223(97)70187-9","article-title":"Early extubation after cardiac operations in neonates and young infants.","volume":"114","author":"Heinle","year":"1997","journal-title":"J Thorac Cardiovasc Surg"},{"key":"R2-20230816","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1444-2892.2002.00144.x","article-title":"Early extubation in congenital heart surgery.","volume":"11","author":"Neirotti","year":"2002","journal-title":"Heart Lung Circ"},{"key":"R3-20230816","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00540-011-1130-7","article-title":"Fast-track postoperative care for neonatal cardiac surgery: a single-institute experience.","volume":"25","author":"Yamasaki","year":"2011","journal-title":"J Anesth"},{"key":"R4-20230816","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1177\/0885066604273481","article-title":"Dexmedetomidine in the treatment of withdrawal syndromes in cardiothoracic surgery patients.","volume":"20","author":"Baddigam","year":"2005","journal-title":"J Intensive Care Med"},{"key":"R5-20230816","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1213\/ane.0b013e318186499c","article-title":"Dexmedetomidine: a novel drug for the treatment of atrial and junctional tachyarrhythmias during the perioperative period for congenital cardiac surgery: a preliminary study.","volume":"107","author":"Chrysostomou","year":"2008","journal-title":"Anesth Analg"},{"key":"R6-20230816","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/01.CCM.0000178183.21883.23","article-title":"The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children.","volume":"33","author":"Finkel","year":"2005","journal-title":"Crit Care Med"},{"key":"R7-20230816","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1097\/MJT.0b013e3180a72255","article-title":"Monitored anesthesia care with a combination of ketamine and dexmedetomidine during cardiac catheterization.","volume":"15","author":"Mester","year":"2008","journal-title":"Am J Ther"},{"key":"R8-20230816","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1213\/01.ane.0000217204.92904.76","article-title":"The use of dexmedetomidine in pediatric cardiac surgery.","volume":"103","author":"Mukhtar","year":"2006","journal-title":"Anesth Analg"},{"key":"R9-20230816","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1460-9592.2006.02031.x","article-title":"Initial experience with dexmedetomidine for diagnostic and interventional cardiac catheterization in children.","volume":"17","author":"Munro","year":"2007","journal-title":"Paediatr Anaesth"},{"key":"R10-20230816","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1053\/j.jvca.2005.07.018","article-title":"Dexmedetomidine-ketamine and propofol-ketamine combinations for anesthesia in spontaneously breathing pediatric patients undergoing cardiac catheterization.","volume":"20","author":"Tosun","year":"2006","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"R11-20230816","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0169-409X(03)00030-9","article-title":"Pharmacokinetics in the newborn.","volume":"55","author":"Alcorn","year":"2003","journal-title":"Adv Drug Deliv Rev"},{"key":"R12-20230816","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.pa.18.040178.000313","article-title":"Developmental aspects of drug conjugation, with special reference to glucuronidation.","volume":"18","author":"Dutton","year":"1978","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"R13-20230816","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/0006-2952(94)90223-2","article-title":"Expression of xenobiotic- metabolizing cytochrome P450 forms in human adult and fetal liver.","volume":"48","author":"Hakkola","year":"1994","journal-title":"Biochem Pharmacol"},{"key":"R14-20230816","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0300-483X(03)00249-X","article-title":"The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children.","volume":"192","author":"Johnson","year":"2003","journal-title":"Toxicology"},{"key":"R15-20230816","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/BF00561473","article-title":"Prenatal and neonatal drug metabolism in man.","volume":"18","author":"Rane","year":"1980","journal-title":"Eur J Clin Pharmacol"},{"key":"R16-20230816","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1213\/ANE.0b013e3181d783c8","article-title":"Population pharmacokinetics of dexmedetomidine in infants after open heart surgery.","volume":"110","author":"Su","year":"2010","journal-title":"Anesth Analg"},{"key":"R17-20230816","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/PCC.0b013e31828a8800","article-title":"A dose-response study of dexmedetomidine administered as the primary sedative in infants following open heart surgery.","volume":"14","author":"Su","year":"2013","journal-title":"Pediatr Crit Care Med"},{"key":"R18-20230816","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.jchromb.2007.01.013","article-title":"Sensitive and specific liquid chromatography-tandem mass spectrometric method for the quantitation of dexmedetomidine in pediatric plasma.","volume":"852","author":"Lee","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"R19-20230816","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/01.PCC.0000282046.66773.39","article-title":"Pharmacokinetics of dexmedetomidine in postsurgical pediatric intensive care unit patients: preliminary study.","volume":"8","author":"D\u00edaz","year":"2007","journal-title":"Pediatr Crit Care Med"},{"key":"R20-20230816","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1097\/00000542-200612000-00009","article-title":"A phase I, two-center study of the pharmacokinetics and pharmacodynamics of dexmedetomidine in children.","volume":"105","author":"Petroz","year":"2006","journal-title":"Anesthesiology"},{"key":"R21-20230816","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/j.1460-9592.2008.02653.x","article-title":"Dexmedetomidine disposition in children: a population analysis.","volume":"18","author":"Potts","year":"2008","journal-title":"Paediatr Anaesth"},{"key":"R23-20230816","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1023\/B:JOPA.0000034404.86036.72","article-title":"Power, selection bias and predictive performance of the Population Pharmacokinetic Covariate Model.","volume":"31","author":"Ribbing","year":"2004","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"R24-20230816","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00431-006-0189-x","article-title":"Population clinical pharmacology of children: modelling covariate effects.","volume":"165","author":"Anderson","year":"2006","journal-title":"Eur J Pediatr"},{"key":"R25-20230816","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1002\/jps.23574","article-title":"A pharmacokinetic standard for babies and adults.","volume":"102","author":"Holford","year":"2013","journal-title":"J Pharm Sci"},{"key":"R26-20230816","doi-asserted-by":"crossref","first-page":"1677","DOI":"10.1126\/science.284.5420.1677","article-title":"The fourth dimension of life: fractal geometry and allometric scaling of organisms.","volume":"284","author":"West","year":"1999","journal-title":"Science"},{"key":"R27-20230816","doi-asserted-by":"crossref","first-page":"313","DOI":"10.2165\/00003088-199733050-00001","article-title":"Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients.","volume":"33","author":"Anderson","year":"1997","journal-title":"Clin Pharmacokinet"},{"key":"R29-20230816","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1213\/00000539-199711000-00033","article-title":"Postoperative pharmacokinetics and sympatholytic effects of dexmedetomidine.","volume":"85","author":"Talke","year":"1997","journal-title":"Anesth Analg"},{"key":"R30-20230816","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1093\/bja\/88.5.669","article-title":"Pharmacokinetics of dexmedetomidine infusions for sedation of postoperative patients requiring intensive caret.","volume":"88","author":"Venn","year":"2002","journal-title":"Br J Anaesth"},{"key":"R31-20230816","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jpeds.2013.10.002","article-title":"A phase II\/III, multicenter, safety, efficacy, and pharmacokinetic study of dexmedetomidine in preterm and term neonates.","volume":"164","author":"Chrysostomou","year":"2014","journal-title":"J Pediatr"},{"key":"R32-20230816","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1124\/dmd.108.021709","article-title":"Regio- and stereospecific N-glucuronidation of medetomidine: the differences between UDP glucuronosyltransferase (UGT) 1A4 and UGT2B10 account for the complex kinetics of human liver microsomes.","volume":"36","author":"Kaivosaari","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"R33-20230816","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1136\/gut.50.2.259","article-title":"Developmental aspects of human hepatic drug glucuronidation in young children and adults.","volume":"50","author":"Strassburg","year":"2002","journal-title":"Gut"},{"key":"R34-20230816","first-page":"515","article-title":"Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human fetal liver and adult lungs.","volume":"24","author":"Shimada","year":"1996","journal-title":"Drug Metab Dispos"},{"key":"R35-20230816","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1016\/S0024-3205(97)01011-4","article-title":"A comparison of hepatic cytochrome P450 protein expression between infancy and postinfancy.","volume":"61","author":"Tateishi","year":"1997","journal-title":"Life Sci"},{"key":"R36-20230816","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1213\/01.ane.0000297421.92857.4e","article-title":"The effects of dexmedetomidine on cardiac electrophysiology in children.","volume":"106","author":"Hammer","year":"2008","journal-title":"Anesth Analg"},{"key":"R37-20230816","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s00134-010-1782-z","article-title":"Electrocardiographic effects of dexmedetomidine in patients with congenital heart disease.","volume":"36","author":"Chrysostomou","year":"2010","journal-title":"Intensive Care Med"},{"key":"R38-20230816","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/00000542-198711000-00019","article-title":"The influence of a right-to-left cardiac shunt on lidocaine pharmacokinetics.","volume":"67","author":"Bokesch","year":"1987","journal-title":"Anesthesiology"},{"key":"R39-20230816","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/bja\/aeg117","article-title":"Drug handling by the lungs.","volume":"91","author":"Boer","year":"2003","journal-title":"Br J Anaesth"},{"key":"R40-20230816","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/(SICI)1520-6017(200004)89:4<519::AID-JPS9>3.0.CO;2-U","article-title":"Influence of cardiac output on dexmedetomidine pharmacokinetics.","volume":"89","author":"Dutta","year":"2000","journal-title":"J Pharm Sci"}],"container-title":["Anesthesia &amp; Analgesia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00000539-201605000-00045","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T14:25:02Z","timestamp":1786112702000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00000539-201605000-00045"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1213\/ane.0000000000000869","relation":{},"ISSN":["0003-2999"],"issn-type":[{"value":"0003-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,5]]}}}